Nevoid Basal Cell Carcinoma Syndrome/Gorlin Syndrome via the PTCH1 Gene
Summary and Pricing 
Test Method
Sequencing and CNV Detection via NextGen Sequencing using PG-Select Capture Probes
| Test Code | Test Copy Genes | Test CPT Code | Gene CPT Codes Copy CPT Code | Base Price | |
|---|---|---|---|---|---|
| 10673 | PTCH1 | 81479 | 81479,81479 | $990 | Order Options and Pricing |
Pricing Comments
Testing run on PG-select capture probes includes CNV analysis for the gene(s) on the panel but does not permit the optional add on of exome-wide CNV analysis. Any of the NGS platforms allow reflex to other clinically relevant genes, up to whole exome or whole genome sequencing depending upon the base platform selected for the initial test.
An additional 25% charge will be applied to STAT orders. STAT orders are prioritized throughout the testing process.
This test is also offered via a custom panel (click here) on our exome or genome backbone which permits the optional add on of exome-wide CNV or genome-wide SV analysis.
Turnaround Time
3 weeks on average for standard orders or 2 weeks on average for STAT orders.
Please note: Once the testing process begins, an Estimated Report Date (ERD) range will be displayed in the portal. This is the most accurate prediction of when your report will be complete and may differ from the average TAT published on our website. About 85% of our tests will be reported within or before the ERD range. We will notify you of significant delays or holds which will impact the ERD. Learn more about turnaround times here.
Targeted Testing
For ordering sequencing of targeted known variants, go to our Targeted Variants page.
Clinical Features and Genetics
Clinical Features
Nevoid basal cell carcinoma syndrome/Gorlin syndrome (OMIM 109400) is characterized by adolescent and early adult multiple jaw keratocysts or basal cell carcinomas (BCCs). Other features include macrocephaly, frontal bossing, coarse facial features, palmar/plantar pits, cardiac and ovarian fibromas, skeletal abnormalities (e.g., bifid ribs, wedge-shaped vertebrae), and facial milia. Infrequently children will develop medulloblastoma (primitive) around 2 years of age (Evans et al. GeneReviews. 2011). It has a birth incidence of ~1:19,000 (Evans et al. 2010. Am J Med Genet A. 152A:327).
Genetics
Nevoid basal cell carcinoma syndrome/Gorlin syndrome is caused by variants in the PTCH1 gene, which encodes a tumor suppressor. Inactivation of the PTCH1 gene results in carcinomas and cysts, whereas alterations in the concentration of PTCH1 during dosage-sensitive hedgehog signaling pathways lead to congenital malformations (Villavicencio et al. Am J Hum Genet Nov;67(5):1047-54, 2000). Nevoid basal cell carcinoma syndrome is inherited in an autosomal dominant manner. Approximately 70-80% individuals have inherited PTCH1 variants from an affected parent, and approximately 20-30% have a de novo (not inherited) variant. It presents with complete penetrance and variable expressivity (Evans et al. GeneReviews. 2011). Variants in PTCH1 include missense, nonsense, splice site, small insertions and deletions, small indels, and large deletions (Human Gene Mutation Database).
Clinical Sensitivity - Sequencing with CNV PG-Select
Sequence analysis of PTCH1 coding exons and exon-intron junctions will be able to detect causative variants in 50-85% of patients with NBCC (Evans and Farndon GeneReviews. 2011). Large deletions of PTCH1 will be detected in approximately 6% of patients with NBCC (Evans and Farndon GeneReviews. 2011).
Testing Strategy
This test provides full coverage of all coding exons of the PTCH1 gene, plus ~10 bases of flanking noncoding DNA. We define full coverage as >20X NGS reads or Sanger sequencing.
Indications for Test
Individuals with a clinical presentation or have a family history of nevoid basal cell carcinoma syndrome/Gorlin syndrome. PTCH1 variants are also found as a cause of holoprosencephaly. This test is specifically designed for heritable germline variants and is not appropriate for the detection of somatic variants in tumor tissue.
Individuals with a clinical presentation or have a family history of nevoid basal cell carcinoma syndrome/Gorlin syndrome. PTCH1 variants are also found as a cause of holoprosencephaly. This test is specifically designed for heritable germline variants and is not appropriate for the detection of somatic variants in tumor tissue.
Gene
| Official Gene Symbol | OMIM ID |
|---|---|
| PTCH1 | 601309 |
| Inheritance | Abbreviation |
|---|---|
| Autosomal Dominant | AD |
| Autosomal Recessive | AR |
| X-Linked | XL |
| Mitochondrial | MT |
Disease
| Name | Inheritance | OMIM ID |
|---|---|---|
| Gorlin Syndrome | AD | 109400 |
Related Tests
| Name |
|---|
| Holoprosencephaly-7 (Autosomal Dominant, Nonsyndromic) via the PTCH1 Gene |
| Medulloblastoma and Nevoid Basal Cell Carcinoma Syndrome/Gorlin Syndrome via the SUFU Gene |
Citations
- Evans et al. GeneReviews. 2011
- Evans et al. GeneReviews. 2011.
- Evans DG, Farndon PA. 2002. Nevoid Basal Cell Carcinoma Syndrome. In: Pagon RA, Adam MP, Bird TD, Dolan CR, Fong C-T, and Stephens K, editors. GeneReviews™, Seattle (WA): University of Washington, Seattle. PubMed ID: 20301330
- Evans DG, Howard E, Giblin C, Clancy T, Spencer H, Huson SM, Lalloo F. 2010. Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service. Am. J. Med. Genet. A 152A: 327–332. PubMed ID: 20082463
- Evans et al. Am J Med Genet A. 2010 Feb;152A(2):327-32.
- Villavicencio et al. (2000). "The sonic hedgehog-patched-gli pathway in human development and disease." Am J Hum Genet. Nov;67(5):1047-54. PubMed ID: 11001584
Ordering/Specimens
Ordering Options
We offer several options when ordering sequencing tests. For more information on these options, see our Ordering Instructions page. To view available options, click on the Order Options button within the test description.
myPrevent - Online Ordering
- The test can be added to your online orders in the Summary and Pricing section.
- Once the test has been added log in to myPrevent to fill out an online requisition form.
- PGnome sequencing panels can be ordered via the myPrevent portal only at this time.
Requisition Form
- A completed requisition form must accompany all specimens.
- Billing information along with specimen and shipping instructions are within the requisition form.
- All testing must be ordered by a qualified healthcare provider.
For Requisition Forms, visit our Forms page
If ordering a Duo or Trio test, the proband and all comparator samples are required to initiate testing. If we do not receive all required samples for the test ordered within 21 days, we will convert the order to the most effective testing strategy with the samples available. Prior authorization and/or billing in place may be impacted by a change in test code.
Specimen Types
Specimen Requirements and Shipping Details
Loading...
×
ORDER OPTIONS
View Ordering Instructions1) Select Test Type
2) Select Additional Test Options
No Additional Test Options are available for this test.